Dxcover

Dxcover is pioneering a multi-cancer early detection platform that leverages infrared spectroscopy and artificial intelligence to analyze liquid biopsy samples. Founded in 2016 and based in Glasgow, the company's technology aims to detect cancer at earlier, more treatable stages by identifying spectral biomarkers in blood serum. Its primary strategic application is the triage of high-risk patient populations, with brain tumors as the lead indication, followed by pancreatic and ovarian cancers. Dxcover is a private, pre-revenue company seeking partnerships and investment to advance its platform through clinical validation and regulatory pathways.

A multi-omic liquid biopsy platform using Fourier-transform infrared (FTIR) spectroscopy on blood serum combined with machine learning/AI to detect spectral biomarkers for early cancer detection.

Dxcover competes in the crowded liquid biopsy space dominated by companies using circulating tumor DNA (ctDNA) analysis (e.g., Grail, Guardant Health, Freenome). Its differentiation lies in its low-cost, holistic spectroscopic analysis versus targeted genomic sequencing, but it must prove this technical approach can match or exceed the performance of established modalities to gain market share.